找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Evidence-Based Psoriasis; Diagnosis and Treatm Tina Bhutani,Wilson Liao,Mio Nakamura Book 2018 Springer International Publishing AG, part o

[復(fù)制鏈接]
樓主: Dangle
21#
發(fā)表于 2025-3-25 05:51:28 | 只看該作者
22#
發(fā)表于 2025-3-25 09:24:59 | 只看該作者
23#
發(fā)表于 2025-3-25 13:17:34 | 只看該作者
Updates in Clinical Dermatologyhttp://image.papertrans.cn/e/image/317574.jpg
24#
發(fā)表于 2025-3-25 17:59:56 | 只看該作者
25#
發(fā)表于 2025-3-25 20:06:19 | 只看該作者
26#
發(fā)表于 2025-3-26 02:29:02 | 只看該作者
https://doi.org/10.1007/978-3-662-11675-3Currently, ultraviolet (UV)-based therapy is one of the first-line therapies for psoriasis due to its high response rate, relative low cost, and minimal generalized immunosuppression compared to other systemic therapies. This chapter will outline the basic principles of photomedicine and photochemis
27#
發(fā)表于 2025-3-26 05:36:37 | 只看該作者
Energie-Effizienzbewertung von Geb?udened to treat psoriasis include cytotoxic and immunomodulatory drugs such as methotrexate, cyclosporine, and apremilast. Another oral agent, acitretin, is a systemic retinoid that affects epidermal proliferation and differentiation as well as immunomodulation. Oral agents for psoriasis are effective a
28#
發(fā)表于 2025-3-26 12:14:03 | 只看該作者
29#
發(fā)表于 2025-3-26 14:54:45 | 只看該作者
Milton Burton,Günther O. Schenckcements have transformed treatment regimens for psoriasis by selectively targeting immune signaling molecules. The aim of this chapter is to review the clinical and research data surrounding these emerging treatments, ranging from those undergoing development to those already in clinical trials. The
30#
發(fā)表于 2025-3-26 18:00:45 | 只看該作者
Alexander Nikuradse,Hans J. Maderseverity of psoriasis. Using two or more therapies with varying mechanisms of action and safety profiles is often necessary to maintain adequate disease control while minimizing toxicity of treatments. Choosing a combination regimen that maximizes safety and efficacy, while at the same time consider
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 22:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
大埔县| 乐山市| 安康市| 龙南县| 清涧县| 仪陇县| 玉溪市| 阜康市| 甘孜| 万全县| 彭水| 安仁县| 武宁县| 闻喜县| 务川| 娄底市| 固原市| 兴山县| 五寨县| 莱西市| 金秀| 金堂县| 墨玉县| 抚远县| 江安县| 新营市| 抚顺市| 张家界市| 称多县| 滨州市| 子长县| 曲阳县| 建昌县| 菏泽市| 衡山县| 靖安县| 绥芬河市| 平顶山市| 饶平县| 会东县| 梓潼县|